Open AccessOutcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease
Author(s) -
Kathryn G. Roberts,
Deqing Pei,
Dario Campana,
Debbie Payne-Turner,
Yongjin Li,
Cheng Cheng,
John T. Sandlund,
Sima Jeha,
John Easton,
Jared Becksfort,
Jinghui Zhang,
Elaine CoustanSmith,
Susana C. Raimondi,
Wing Leung,
Mary V. Relling,
William E. Evans,
James R. Downing,
Charles G. Mullighan,
ChingHon Pui
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - Norwegian
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.55.4105
Subject(s) - minimal residual disease , medicine , fusion gene , breakpoint cluster region , oncology , abl , tyrosine kinase , philadelphia chromosome , cancer research , leukemia , immunology , chromosomal translocation , gene , genetics , biology , receptor
BCR-ABL1–like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1–like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom